Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case
Source: SeekingAlpha
2026-02-26 12:01:16 ET
Thesis
Read the full article on Seeking Alpha
For further details see:
Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case
Arcutis Biotherapeutics Inc.
NASDAQ: ARQT
ARQT Trading
3.8% G/L:
$24.475 Last:
346,296 Volume:
$23.92 Open:
ARQT Latest News
March 05, 2026 09:00:00 am
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
March 03, 2026 08:00:00 am
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
February 27, 2026 04:00:00 pm
Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference
ARQT Stock Data
$3,301,042,082
98,483,722
0.17%
104
N/A
Biotechnology & Life Sciences
Healthcare
US
Westlake Village
